Table 1 Models output for assessing the variation in antibiotic consumption in the Haemato-Oncology unit (HO ward and HSCT, combined) expressed as relative risk (RR) with 95%CI.
From: Impact of a two step antimicrobial stewardship program in a paediatric haematology and oncology unit
First intervention (FN institution guidelines publication and dissemination) | Second intervention (structured ASP) | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
Immediate impact | Variation by months (slope variation) | Immediate impact | Variation by months (slope variation) | |||||||||
% | RR (95% CI) | p-value | % | RR (95% CI) | p-value | % | RR (95% CI) | p-value | % | RR (95% CI) | p-value | |
Total antibiotics | −6.80 | 0.93 (0.87–1) | 0.063 | −1.0 | 0.99 (0.98–1) | 0.006 | −1.1 | 0.99 (0.94–1.04) | 0.678 | 0.2 | 1 (1–1.01) | 0.515 |
Meropenem | −25.5 | 0.74 (0.58–0.95) | 0.019 | 8.1 | 1.08 (1.06–1.1) | 0.000 | −43.0 | 0.57 (0.49–0.66) | 0.000 | −3.4 | 0.97 (0.95–0.98) | 0.000 |
Piperacillin-tazobactam | 185.5 | 2.86 (2.19–3.72) | 0.000 | −10.2 | 0.9 (0.87–0.93) | 0.000 | 15.0 | 1.15 (1.02–1.3) | 0.028 | 1.2 | 1.01 (1–1.03) | 0.126 |
Third-generation cephalosporins | −66.5 | 0.33 (0.25–0.45) | 0.000 | 6.4 | 0.94 (0.91–0.96) | 0.000 | 37.5 | 1.37 (1.07–1.77) | 0.013 | 0.7 | 1.01 (0.98–1.04) | 0.622 |
Quinolones | −13.3 | 0.87 (0.59–1.27) | 0.461 | 26.7 | 1.27 (1.21–1.33) | 0.000 | 16.6 | 1.17 (0.9–1.52) | 0.249 | −13.1 | 0.87 (0.83–0.9) | 0.000 |
Amikacin | 21.9 | 1.22 (0.98–1.52) | 0.080 | −1.0 | 0.99 (0.97–1.01) | 0.390 | 13.7 | 1.14 (0.99–1.31) | 0.075 | −2.4 | 0.98 (0.96–0.99) | 0.005 |
Vancomycin-Teicoplanin | −13.3 | 0.87 (0.73–1.04) | 0.116 | 1.6 | 1.02 (1–1.03) | 0.057 | −8.1 | 0.92 (0.82–1.03) | 0.140 | −2.2 | 0.98 (0.97–0.99) | 0.002 |
